Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Ethnopharmacological Relevance: Isochlorgenic acid C (IAC), one of the bioactive compounds of Lonicera japonica, exhibited diverse pharmacological effects. However, its pharmacokinetic properties and bioavailability remained unresolved.
Aim Of The Study: To determine the absolute bioavailability in rats and the dose proportionality on the pharmacokinetics of single oral dose of IAC.
Materials And Methods: A validated HPLC-MS method was developed for the determination of IAC in rat plasma. Plasma concentration versus time data were generated following oral and intravenous dosing. The pharmacokinetic analysis was performed using DAS 3.0 software analysis. Absolute bioavailability in rats was determined by comparing pharmacokinetic data after administration of single oral (5, 10 and 25mgkg(-1)) and intravenous (5mgkg(-1)) doses of IAC. The dose proportionality of AUC(0-∞) and Cmax were analyzed by linear regression.
Results: Experimental data showed that absolute oral bioavailability of IAC in rats across the doses ranged between 14.4% and 16.9%. The regression analysis of AUC(0-∞) and Cmax at the three doses (5, 10 and 25mgkg(-1)) indicated that the equations were y=35.23x+117.20 (r=0.998) and y=121.03x+255.74 (r=0.995), respectively.
Conclusions: A new HPLC-MS method was developed to determine the bioavailability and the dose proportionality of IAC. Bioavailability of IAC in rats was poor and both Cmax and AUC(0-∞) of IAC had a positive correlation with dose. Evaluation of the pharmacokinetics of IAC will be useful in assessing concentration-effect relationships for the potential therapeutic applications of IAC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jep.2016.03.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs.
J Vet Pharmacol Ther
September 2025
Elanco Animal Health, Sèvres, France.
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.
View Article and Find Full Text PDFA Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B Therapy.
Mol Ther
September 2025
Be Biopharma, Cambridge, MA, 02139, USA. Electronic address:
Hemophilia B gene therapy treatments currently have not addressed the need for predictable, durable, active, and redosable factor IX (FIX). Unlike conventional gene therapy, engineered B Cell Medicines (BCMs) are durable, redosable, and titratable, and thus have the potential to address significant unmet needs in the Hemophilia B treatment paradigm. BE-101 is an autologous BCM comprised of expanded and differentiated B lymphocyte lineage cells genetically engineered ex vivo to secrete FIX-Padua.
View Article and Find Full Text PDFEngineering Spiropyran-Based Ratiometric F MRI Probes with Ultralarge Chemical Shift Variations.
ACS Sens
August 2025
Key Laboratory of Resource Chemistry of Ministry of Education, Shanghai Key Laboratory of Rare Earth Functional Materials, and Department of Chemistry, Shanghai Normal University, Shanghai 200234, China.
Fluorine magnetic resonance imaging (F MRI) is a rapidly growing field with significant potential for clinical diagnostics, but it is hindered by inherently low sensitivity. Developing stimuli-responsive F MRI probes with dual-signal capabilities enhances diagnostic sensitivity but remains highly challenging. Herein, we designed pH-activatable F MRI probes based on fluorinated spiropyrans, engineered through spiro-isomerism (pH-triggered merocyanine-spiropyran interconversion) and positional-isomerism (strategically tuning F-substitution positions on the spiropyran core) strategies to achieve unprecedented ratiometric F NMR chemical shift variations (Δδ) of up to 13 ppm.
View Article and Find Full Text PDFFirst-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.
J Immunother Cancer
August 2025
Institut Gustave-Roussy, Villejuif, France.
Background: Inducible costimulator (ICOS) receptor belongs to the CD28/CTLA immunoglobulin super family, whose expression is restricted to T cells and is weakly expressed on resting TH17, follicular helper T cells, and regulatory T cells, but is highly induced on CD4+ and CD8+ T cells on activation by T-cell receptors. ICOS stimulation downstream effects include activation of conventional CD4+cells and cytotoxic CD8+cells, resulting in a durable antitumor response in preclinical models.
Methods: As part of a larger first-in-human study (GSK Study 204691), this study focused on 2 cohorts of 25 and 67 participants enrolled in a dose escalation and pharmacokinetic/pharmacodynamic (PK/PD) analysis of the ICOS agonist feladilimab (GSK3359609) as monotherapy.
Pharmacokinetics and safety evaluation of anemoside B4 in healthy Beagle dogs.
Front Vet Sci
July 2025
College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Background: Anemoside B4 (AB4), a pentacyclic triterpenoid saponin extracted from the traditional Chinese medicinal herb , has shown anti-inflammatory and immunomodulatory effects in both preclinical and clinical studies. However, pharmacokinetic and safety data in dogs remain limited. This study aimed to evaluate the pharmacokinetics, bioavailability, and safety of AB4 in healthy Beagle dogs.
View Article and Find Full Text PDF